Hogan, et al. – Summary
Hogan SA, Levesque MP, Cheng PF. Melanoma Immunotherapy: Next-Generation Biomarkers. Front Oncol. 2018 May 29;8:178. Available at: https://www.frontiersin.org/articles/10.3389/fonc.2018.00178/full
Immune checkpoint inhibitors (anti-CTLA4 and anti-PD1) are now widely used treatment against metastatic melanoma. Although they greatly improved the overall survival of some patients, a significant portion still do not benefit from the drugs. Clinicians would greatly benefit from markers allowing them to predict which patient is most likely to respond to the treatment in order to save precious time and money on inefficient therapy. In this review, we sought to give an overview of the biomarker research field in the context of immunotherapy treatment for melanoma, with a focus on human studies and new technologies, allowing more precise and comprehensive analysis than previously achievable.